| 產(chǎn)品編號 | bs-0530R-PE-Cy7 |
| 英文名稱 | Rabbit Anti-PPAR gamma/PE-Cy7 Conjugated antibody |
| 中文名稱 | PE-Cy7標記的過氧化酶活化增生受體γ抗體 |
| 別 名 | CIMT1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; PPAR gamma; PPARG; PPARG1; PPARG2; PPARG3; CIMT1; GLM1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR gamma; PPAR-gamma; PPARG_HUMAN; PPAR gamma 1; PPAR gamma 2; PPAR gamma 3; PPAR gamma-1; PPAR gamma-2; PPAR gamma-3. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 免疫學 信號轉(zhuǎn)導 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 糖尿病 內(nèi)分泌病 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, Rat, (predicted: Chicken, Pig, Cow, Rabbit, Sheep, ) |
| 產(chǎn)品應(yīng)用 | Flow-Cyt=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 57kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PPAR Gamma |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The PPAR gamma antibody mainly is exist in the white fat organization, the fat for the PPAR gamma is born, blood sugar stability, the disease respond, the artery gruel kind hardens to rise the important function with the tumor occurrence of etc. all, but concerning the PPAR gamma to bone of function is a new research heat to order in recent years.A PPAR of many researches report gamma was go together with the body is after activate can the function promote many capable cells divided to increase to living but repress the ossification cell to divide to cause the bone measure the decrease or bone softs toward the fat cell in the marrow, the PPAR gamma promotes the ability and bones that the fat cell divide metabolize closely related, the performance is increasing along with the growth marrow fat content of the age, the ossification cell metabolism the outcome reduce, the different construction PPAR gamma 2 have the important function. Function: Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Subunit: Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with TGFB1I1. Interacts with DNTTIP2. Interacts with PRMT2. Subcellular Location: Nucleus. Tissue Specificity: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary. DISEASE: Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer. Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat. Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia. Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility. Similarity: Belongs to the nuclear hormone receptor family. NR1 subfamily. Contains 1 nuclear receptor DNA-binding domain. Database links: Entrez Gene: 5468 Human Entrez Gene: 19016 Mouse SwissProt: P37231 Human SwissProt: P37238 Mouse Unigene: 162646 Human Unigene: 3020 Mouse Unigene: 23443 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 類固醇受體（Steroid Receptors） 過氧化物酶體增殖物激活受體γ（PPARγ）主要存在于白色脂肪組織，PPARγ對于脂肪生成、血糖穩(wěn)定、炎癥反應(yīng)、動脈粥樣硬化和腫瘤等的發(fā)生都起到重要的作用。主要在脂肪細胞內(nèi)表達。PPARγ是噻唑烷二酮類藥物（TZDs）作用的藥靶，又是脂肪細胞分化的重要調(diào)節(jié)因子。經(jīng)研究發(fā)現(xiàn)，PPARγ在肥胖及胰島素抵抗的發(fā)病機制中具有十分重要的意義，是治療糖尿病、肥胖等代謝性疾病的重要藥靶。 過氧化物酶體增殖物激活受體γ（PPARγ）屬Ⅱ型核受體超家族成員，主要在脂肪細胞內(nèi)表達。PPARγ是噻唑烷二酮類藥物（TZDs）作用的藥靶，又是脂肪細胞分化的重要調(diào)節(jié)因子?，F(xiàn)有研究（包括一次于美國加州大學進行的研究）發(fā)現(xiàn)PPARγ在肥胖及胰島素抵抗的發(fā)病機制中具有十分重要的意義，是治療糖尿病、肥胖等代謝性疾病的重要藥靶。目前，該受體蛋白質(zhì)水平的篩選模式已經(jīng)建立，并正在建立該受體的報告基因的細胞水平篩選評價模式。 |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
